Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iqvia Holdings Inc (NY: IQV )

223.37 +1.23 (+0.55%)
Official Closing Price Updated: 7:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,052,930
Open 223.53
Bid (Size) 173.00 (1)
Ask (Size) 280.72 (1)
Prev. Close 222.14
Today's Range 222.97 - 227.56
52wk Range 167.42 - 261.73
Shares Outstanding 182,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Forecasting The Future: 8 Analyst Projections For IQVIA Hldgs
Via Benzinga
IQV Stock Earnings: IQVIA Hldgs Beats EPS, Beats Revenue for Q1 2024
IQV stock results show that IQVIA Hldgs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-3.05%
-3.05%
1 Month
-8.07%
-8.07%
3 Month
+5.99%
+5.99%
6 Month
+13.27%
+13.27%
1 Year
+21.13%
+21.13%

More News

Read More
IQVIA Reports First-Quarter 2024 Results
From IQVIA Holdings Inc.
Via Business Wire
Analysts Are Pounding the Table on These 3 Stocks: April 2024
Via InvestorPlace
IQVIA Celebrates Wendy Stewart and Susan Barnes, Winners of Healthcare Businesswoman's Association Luminary and Rising Star Awards
From IQVIA
Via Business Wire
Peering Into IQVIA Hldgs's Recent Short Interest
Via Benzinga
Peering Into IQVIA Hldgs's Recent Short Interest
Via Benzinga
How Is The Market Feeling About IQVIA Hldgs?
Via Benzinga
IQVIA to Announce First-Quarter 2024 Results on May 2, 2024
From IQVIA Holdings Inc.
Via Business Wire
Salesforce & IQVIA Expand Partnership: Life Sciences Cloud Gets A Superpower Boost
Via Benzinga
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
From IQVIA
Via Business Wire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Via The Motley Fool
Earnings Scheduled For February 14, 2024
Via Benzinga
Peeling Back The Layers: Exploring IQVIA Hldgs Through Analyst Insights
Via Benzinga
Expert Ratings For IQVIA Hldgs
Via Benzinga
IQVIA CFO Ron Bruehlman to Speak at Barclays Annual Global Healthcare Conference on March 13, 2024
From IQVIA Holdings Inc.
Via Business Wire
IQVIA Publishes its 2023 Environmental, Social and Governance Report
From IQVIA
Via Business Wire
Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report
From IQVIA
Via Business Wire
IQVIA CFO Ron Bruehlman to Speak at Citi’s Unplugged Medtech and Life Sciences Access Day on February 29, 2024
From IQVIA Holdings Inc.
Via Business Wire
Stocks Rebound As Investor Focus Shifts To Earnings, Bitcoin Tops $1 Trillion Value: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Healthcare Analytics-Focused IQVIA Says 2023 Performance Solid Despite Challenging Macro Environment
Via Benzinga
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
IQVIA Reports Fourth-Quarter and Full-Year 2023 Results; Issues Full-Year 2024 Guidance
From IQVIA Holdings Inc.
Via Business Wire
IQVIA Named to Fortune® World's Most Admired Companies™ List, Ranked #1 in Its Sector for the Third Consecutive Year
From IQVIA
Via Business Wire
IQVIA to Announce Fourth-Quarter and Full-Year 2023 Results on February 14, 2024
From IQVIA Holdings Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.